Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.31
-7.1%
$1.56
$1.21
$7.97
$45.38M1.1133,953 shs19,690 shs
Accuray Incorporated stock logo
ARAY
Accuray
$1.70
-2.9%
$2.37
$1.51
$4.30
$168.59M1.48531,140 shs426,282 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$7.06
-7.1%
$8.42
$3.78
$13.62
$389.85M1.73178,753 shs92,154 shs
Soliton, Inc. stock logo
SOLY
Soliton
$22.58
$21.55
$7.40
$22.60
$487.66M0.19347,827 shsN/A
The Westaim Co. stock logo
WEDXF
Westaim
$2.84
+1.1%
$2.68
$2.18
$2.99
$365.34M0.4528,473 shs38,794 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
+0.71%-1.40%-6.00%-41.25%-59.48%
Accuray Incorporated stock logo
ARAY
Accuray
-2.23%-17.84%-27.08%-29.15%-51.12%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-1.68%+3.12%+0.40%-11.63%-5.24%
Soliton, Inc. stock logo
SOLY
Soliton
0.00%0.00%0.00%0.00%0.00%
The Westaim Co. stock logo
WEDXF
Westaim
+1.07%+4.41%+8.81%+7.58%+30.28%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
4.0638 of 5 stars
3.55.00.04.20.01.70.6
Accuray Incorporated stock logo
ARAY
Accuray
3.5776 of 5 stars
3.50.00.04.62.11.70.6
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
0.4255 of 5 stars
0.00.00.04.21.73.30.0
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17370.74% Upside
Accuray Incorporated stock logo
ARAY
Accuray
3.00
Buy$8.25385.29% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Latest ARAY, PLSE, WEDXF, SOLY, and APYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.87N/AN/A$0.78 per share1.68
Accuray Incorporated stock logo
ARAY
Accuray
$430.55M0.39N/AN/A$0.56 per share3.04
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K556.93N/AN/A$0.81 per share8.72
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A$1.46 per shareN/A
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M42.33$1.46 per share1.94$3.95 per share0.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Confirmed)
Accuray Incorporated stock logo
ARAY
Accuray
-$9.28M-$0.22N/A34.00N/A-4.99%-42.34%-4.50%8/14/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%8/8/2024 (Estimated)
Soliton, Inc. stock logo
SOLY
Soliton
-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/A
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.18N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest ARAY, PLSE, WEDXF, SOLY, and APYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.18N/A+$0.18N/AN/AN/A  
5/1/2024Q3 2024
Accuray Incorporated stock logo
ARAY
Accuray
-$0.01-$0.06-$0.05-$0.06$114.60 million$101.13 million    
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A
3/27/2024Q4 2023
The Westaim Co. stock logo
WEDXF
Westaim
N/A$0.26+$0.26$0.26N/A$1.67 million
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Accuray Incorporated stock logo
ARAY
Accuray
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Accuray Incorporated stock logo
ARAY
Accuray
3.53
1.58
0.84
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
Soliton, Inc. stock logo
SOLY
Soliton
N/A
5.47
5.37
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Accuray Incorporated stock logo
ARAY
Accuray
64.08%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
Soliton, Inc. stock logo
SOLY
Soliton
35.11%
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Accuray Incorporated stock logo
ARAY
Accuray
3.78%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
71.50%
Soliton, Inc. stock logo
SOLY
Soliton
12.00%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Accuray Incorporated stock logo
ARAY
Accuray
1,02499.17 million95.42 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million15.74 millionOptionable
Soliton, Inc. stock logo
SOLY
Soliton
1421.60 million19.01 millionNot Optionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.64 million123.22 millionNot Optionable

ARAY, PLSE, WEDXF, SOLY, and APYX Headlines

SourceHeadline
Westaim Announces Pricing of Skyward Specialty’s Secondary OfferingWestaim Announces Pricing of Skyward Specialty’s Secondary Offering
businesswire.com - May 6 at 9:31 PM
Westaim Announces Sale of Skyward Specialty Shares Under Secondary OfferingWestaim Announces Sale of Skyward Specialty Shares Under Secondary Offering
finance.yahoo.com - May 6 at 10:07 AM
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Accuray logo

Accuray

NASDAQ:ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Soliton logo

Soliton

NASDAQ:SOLY
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.